Interrelationship between pharmacokinetics and pharmacodynamics in choosing the appropriate antibiotic and the dosage regimen for treating acute exacerbations of chronic bronchitis

Respiratory Medicine

Volumn 92, Issue 7, 1998, Pages 895-901

  Cazzola, M ^a,c   Matera, M G ^b  

^a CARDARELLI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; DIRITHROMYCIN; MINOCYCLINE;

ACUTE DISEASE; ANTIBIOTIC THERAPY; CHRONIC BRONCHITIS; HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

EID: 0031693711     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(98)90187-1     Document Type: Review

References (58)

1. Ball P, Tillotson G, Wilson R. Chemotherapy for chronic bronchitis. Controversies. Presse Med 1995; 24: 189-194.
2. Ball P, Harris JM, Lowson D, Tillotson G, Wilson R. Acute infective exacerbations of chronic bronchitis. Q J Med 1995; 88: 61-68.
3. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146: 1067-1083.
4. Cazzola M. Problems and prospectives in the antibiotic treatment of lower respiratory tract infections. Pulm Pharmacol 1994; 7: 139-152.
5. Cazzola M. Infektionen der tiefen Atemwege in der Allgemeinpraxis. Infection 1987; 15: (Suppl. 3): S113-S119.
6. Floreani AA, Buchalter SE, Sisson JH, Thompson AB, Rennard SI. Chronic bronchitis. In: Pennington JE, ed. Respiratory Infections: Diagnosis and Management. 3rd edn. New York: Raven Press 1994, 149-192.
7. Smith CB, Golden C, Klauber MR, Kanmer R, Renzetti A. Interaction between viruses and chronic bronchitis. J Infect Dis 1976; 134: 552-561.
8. MacFarlane JT, Colville A, Guion A, MacFarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in community. Lancet 1993; 341: 511-514.
9. Saint S, Bent S, Vittinghof E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. JAMA 1995; 273: 957-960.
10. Anthonisen NR, Manfreda J, Warren CPW, Hershfeild ES, Harding GKM, Nelson NA. Antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
11. Siafakas NM, Vermeire P, Pride NB et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398-1420.
12. Staley H, McDade HB, Paes D. Is an objective assessment of antibiotic therapy in exacerbations of chronic bronchitis possible? J Antimicrob Chemother 1993; 31: 193-199.
13. Taylor DC, Clancy RL, Cripps AW, Butt H, Bartlett L, Murree-Allen K. An alteration in the host-parasite relationship in subjects with chronic bronchitis prone to recurrent episodes of acute bronchitis. Immunol Cell Biol 1994; 72: 143-151.
14. Cazzola M. Lower respiratory tract infections in general practice. RSM Int Congr Symp Series 1986; 109: 45-55.
15. Craig WA. Selecting the antibiotic. Hospit Pract 1993; 28 (Suppl. 1): 16-20.
16. Nix DE, Schentag JJ. Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics. Diagn Microbiol Infect Dis 1995; 22: 71-76.
17. Cars O. Efficacy of beta-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics. Diagn Microbiol Infect Dis 1997; 27: 29-34.
18. Lode H, Boeckh M, Schaberg T. Human pharmacokinetics of macrolide antibiotics. In: Bryskier AJ, Butzler J-P, Neu HC, Tulkens PM, eds. Macrolides. Chemistry, Pharmacology and Clinical Uses Paris: Arnette-Blackwell, 1993, 409-420.
19. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96.
20. Craig WA, Ebert S. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis 1991; 74 (Suppl.): 63-70.
21. Odenhold-Tornqvist I, Holm SE, Cars O. Pharmacodynamic effects of subinhibitory antibiotic concentrations. Scand J Infect Dis 1991; 74 (Suppl.): 94-101.
22. Craig WA. Post-antibiotic effects in experimental infection models: relationship to in vitro phenomena and to treatment of infections in man. J Antimicrob Chemother 1993; 31 (Suppl. D): 149-158.
23. Craig WA, Kinetics of antibiotics in relation to effective and convenient outpatient parenteral therapy. Intern J Antimicrob Agents 1995; 5: 19-22.
24. Eagle H, Musselman AD. The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms. J Exp Med 1948; 88: 99-131.
25. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 157: 831-847.
26. Leggett JE, Fantin B, Ebert S et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159: 281-292.
27. Craig WA. The pharmacokinetics of cefpirome: rationale for a twelve-hour dosing regimen. Scand J Infect Dis 1993; 91 (Suppl.): 33-40.
28. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 9 (Suppl. 3): 38-44.
29. Schentag JJ, Smith IL, Swanson DJ et al. Role for dual individualization with cefmenoxime. Am J Med 1984; 77 (Suppl. 6A): 43-50.
30. Craig WA. Antimicrobial resistance issues of the future. Diagn Microbiol Infect Dis 1996; 25: 213-217.
31. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in acute otitis media. Pediatr Infect Dis J 1996; 15 (Suppl. 3): 255-259.
32. Bergogne-Bérézin E. New concepts in the pulmonary disposition of antibiotics. Pulm Pharmacol 1995; 8: 65-81.
33. Cazzola M, Diamare F, Vinciguerra A, Salzillo A, Calderaro F. La penetrazione polmonare degli antibiotici e il suo impatto clinico. Rass Pat App Respir 1996; 11: 134-147.
34. Maesen FPV, Beenwkes H, Davies BI, Buytendijk H, Brombacher PJ, Weesman J. Bacampicillin in acute exacerbation of chronic bronchitis: a dose-range study. J Antimicrob Chemother 1976; 2: 279-285.
35. Maesen FPV, Geraedts WH, Davies BI. Cefaclor in the treatment of chronic bronchitis. J Antimicrob Chemother 1990; 26: 456-457.
36. Maesen FPV, Davies BI, van den Bergh JJAM, Gubbelmans HLL, Meek JCE, Geraedts WH. Cefodizime and cefotaxime in acute exacerbations of chronic bronchitis: a randomized double blind prospective study in 180 patients. J Antimicrob Chemother 1990; 25: 412-413.
37. Maesen FPV, Davies BI, van den Bergh JJAM. Doxycycline and minocycline in the treatment of respiratory infections: a double-blind comparative clinical, microbiological and pharmacokinetic study. J Antimicrob Chemother 1989; 23: 123-129.
38. Walstad RA. Concentrations of antibiotics in sputum. Res Clin Forums 1990; 12: 87-92.
39. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995; 108: 43S-52S.
40. Drusano GL, Goldstein FW. Relevance of the Alexander Project: pharmacodynamic considerations. J Antimicrob Chemother 1996; 38 (Suppl. A): 141-154.
41. Bergogne-Bérézin E. Tissue distribution of dirithromycin: comparison with erythromycin. J Antimicrob Chemother 1993; 31 (Suppl. C): 77-87.
42. Gaillat J. A multicentre study comparing the safety and efficacy of dirithromycin with erythromycin in the treatment of bronchitis. J Antimicrob Chemother 1993; 31 (Suppl. C): 139-151.
43. Sides GD. Clinical efficacy of dirithromycin in acute exacerbation of chronic bronchitis. J Antimicrob Chemother 1993; 31 (Suppl. C): 131-138.
44. Cazzola M, Matera MG, Tufano MA et al. Pulmonary penetration of dirithromycin in patients suffering from acute exacerbation of chronic bronchitis. Pulm Pharmacol 1994; 7: 377-381.
45. Honeybourne D, Baldwin DR. The site concentrations of antimicrobial agents in the lung. J Antimicrob Chemother 1992; 30: 249-260.
46. Cazzola M, Caputi M, Santangelo G, Vinciguerra A, Di Perna F, Polverino M. A five-day course of dirithromycin in the treatment of acute exacerbation of severe chronic obstructive pulmonary disease. J Chemother 1997; 9: 279-284.
47. Cazzola M. Pulmonary pharmacokinetics of dirithromycin allow a 5-day treatment of acute bacterial exacerbation of chronic bronchitis. Drugs of Today 1995; 31: 105-109.
48. Matera MG, Tufano MA, Polverino M, Rossi F, Cazzola M. Pulmonary concentrations of dirithromycin and erythromycin during acute exacerbation of mild chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 97-102.
49. Neu HC. Activity of macrolides against common pathogens in vitro. In: Bryskier AJ, Butzler J-P, Neu HC, Tulkens PM, eds. Macrolides. Chemistry, Pharmacology and Clinical Uses. Paris: Arnette-Blackwell, 1993, 167-182.
50. Sides GD, Cerimele BJ, Black HR, Busch U, DeSante KA. Pharmacokinetics of dirithromycin. J Antimicrob Chemother 1993; 31 (Suppl. C): 65-75.
51. Forsgren J, Samuelson A, Ahlin A, Jonasson J, Rynnel-Dagöö B, Lindberg A. Haemophilus influenzae resides and multiplies intracellularly in human adenoid tissue as demonstrated by in situ hybridization and bacterial viability assay. Infect Immun 1994; 62: 673-679.
52. Thornsberry C. Cefaclor AF. Correlation of microbiology and clinical outcome. Postgrad Med J 1992; 68 (Suppl. 3): S10-S16.
53. Simon C, Gatzemeier U. Serum and sputum levels of cefaclor. Postgrad Med J 1979; 55 (Suppl. 4): 30-34.
54. Brumfitt W. Introductory remarks. Postgrad Med J 1992; 68 (Suppl. 3): S1-S2.
55. Cazzola M, Matera MG, Cirella M et al. Penetrazione del cefaclor nell'espettorato dopo somministrazione singola e multipla: confronto fra la preparazione a rilascio classico e una formulazione a rilascio modificato. Giorn It Ric Clin Ter 1995; 16: 37-41.
56. Neu HC. Activity of macrolides agains common pathogens in vitro. In: Bryskier AJ, Butzler J-P, Neu HC, Tulkens PM, eds. Macrolides. Chemistry, Pharmacology and Clinical Uses. Paris: Arnette-Blackwell, 1993, 167-182.
57. Derriennic M. Antimicrobial activity of dirithromycin. Drugs of Today 1995; 31 (Suppl. C): 23-28.
58. Rowland M, Tozer TN. Clinical Pharmacokinetics. Philadelphia: Lea & Febiger, 1980, 197-217.